These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31378579)

  • 21. Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab.
    Cortellini A; Napoleoni L; Cimini N; Parisi A; Pavese F; DʼOrazio C; Verna L; Porzio G; Ficorella C
    J Clin Neuromuscul Dis; 2018 Dec; 20(2):99-100. PubMed ID: 30439756
    [No Abstract]   [Full Text] [Related]  

  • 22. Nivolumab-induced lichen planus.
    Yilmaz M; Mese SG; Celik U
    J Oncol Pharm Pract; 2020 Apr; 26(3):758-760. PubMed ID: 31382865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
    Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect.
    Grimaux X; Delva R; Jadaud E; Croue A
    Australas J Dermatol; 2019 Aug; 60(3):e235-e236. PubMed ID: 30592031
    [No Abstract]   [Full Text] [Related]  

  • 25. Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report.
    Dionese M; Pierantoni F; Maruzzo M; Bimbatti D; Deppieri FM; Maran M; Gardiman MP; Basso U
    Anticancer Drugs; 2021 Feb; 32(2):222-225. PubMed ID: 32868643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
    Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
    J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A Case of Rheumatoid Arthritis Developed during Treatment with Nivolumab for Renal Cell Carcinoma].
    Tomizawa M; Nakai Y; Maesaka F; Owari T; Hara R; Miyake M; Inoue T; Anai S; Tanaka N; Fujimoto K
    Hinyokika Kiyo; 2018 Oct; 64(10):397-401. PubMed ID: 30543737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors.
    Azari AE; Stratton R; Singh A
    Rheumatology (Oxford); 2021 May; 60(5):e167-e168. PubMed ID: 33280022
    [No Abstract]   [Full Text] [Related]  

  • 29. Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab.
    Mizutani K; Ito T; Takahara K; Ando R; Ishihara T; Yasui T; Shiroki R; Miyake H; Koie T
    Medicine (Baltimore); 2021 Apr; 100(13):e25402. PubMed ID: 33787647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case Report of Akathisia in a Patient With Metastatic Renal Cell Carcinoma on Nivolumab.
    Ho SX; Gass CE; Ruark JM
    J Acad Consult Liaison Psychiatry; 2021; 62(1):119-122. PubMed ID: 33008604
    [No Abstract]   [Full Text] [Related]  

  • 31. Bullous pemphigoid associated with the 480-mg nivolumab dose in a patient with metastatic renal cell carcinoma.
    Palla AR; Smith E; Doll D
    Immunotherapy; 2019 Oct; 11(14):1187-1192. PubMed ID: 31462105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
    De Giorgi U; Cartenì G; Giannarelli D; Basso U; Galli L; Cortesi E; Caserta C; Pignata S; Sabbatini R; Bearz A; Buti S; Lo Re G; Berruti A; Bracarda S; Cognetti F; Rastelli F; Fornarini G; Porta C; Turci D; Sternberg CN; Procopio G;
    BJU Int; 2019 Jan; 123(1):98-105. PubMed ID: 29956884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A Case of Nivolumab-Induced Isolated Adrenocorticotropic Hormone Deficiency Presenting Dyspnea].
    Ito K; Uchida T; Manabe Y; Miyazaki Y; Itoh H; Mishina M; Okuno H
    Hinyokika Kiyo; 2018 Oct; 64(10):391-395. PubMed ID: 30543736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting.
    Amores Bermúdez J; Osman García I; Unda Urzáiz M; Jiménez Marrero P; Ledo Cepero MJ; Llarena R; Flores Martín J; Abad Vivas-Pérez JI; Rodrigo Aliaga M; Juarez Soto A
    Actas Urol Esp (Engl Ed); 2019 Sep; 43(7):364-370. PubMed ID: 31097211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nivolumab-related pancreatitis with autoimmune pancreatitis-like imaging features.
    Tanaka T; Sakai A; Kobayashi T; Masuda A; Shiomi H; Kodama Y
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1274. PubMed ID: 30828866
    [No Abstract]   [Full Text] [Related]  

  • 36. Renal damage secondary to check-point inhibitors.
    Moliz C; Cavero T; Morales E; Gutiérrez E; Alonso M; Praga M
    Nefrologia (Engl Ed); 2020; 40(2):206-208. PubMed ID: 31615688
    [No Abstract]   [Full Text] [Related]  

  • 37. [A Case of Late Onset Nivolumab-Induced Interstitial Nephritis in a Patient with Metastatic Renal Cell Carcinoma].
    Hattahara K; Yamasaki T; Sawada A; Tanigaki K; Endo S; Teramoto Y; Banno H; Fuchigami Y; Suzuki R; Fujiwara M; Hida T; Yoshino T; Kita Y; Goto T; Akamatsu S; Saito R; Kobayashi T; Inoue T; Ogawa O
    Hinyokika Kiyo; 2019 May; 65(5):157-161. PubMed ID: 31247693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nivolumab plus ipilimumab in metastatic colorectal cancer.
    Gourd E
    Lancet Oncol; 2018 Mar; 19(3):e139. PubMed ID: 29395861
    [No Abstract]   [Full Text] [Related]  

  • 39. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M
    J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
    Zarrabi K; Wu S
    Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.